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Background Osteolysis causes recurrent pain and disability after total hip arthroplasty 
(THA). We investigated the effect of the human monoclonal antibody denosumab on 
osteolytic lesion activity in patients undergoing revision THA surgery to demonstrate the 
biological proof-of-concept for a non-surgical treatment for the disease. 
Methods We did a phase two, randomised, double-blind, placebo-controlled superiority trial 
at Sheffield Teaching Hospitals (Sheffield, England). Eligible patients aged 30 years or older 
and scheduled for revision surgery for symptomatic osteolysis were randomly allocated (1:1) 
to subcutaneous denosumab (60mg single-dose) or placebo by an independent pharmacist 
using a random number table. The primary outcome was the between-group difference in 
osteoclast number/mm of bone surface of biopsies taken from the osteolytic membrane-bone 
interface at surgery eight weeks later, measured by quantitative histomorphometry. Adverse 
events were analysed in all randomised participants. This trial is registered with the EU 
Clinical Trials Register (EudraCT 2011-000541-20). 
Findings Between December 19, 2012 and June 24, 2018, 51 patients were reviewed for 
eligibility, of whom 24 were randomly assigned to study treatment. Two had their revision 
surgery cancelled for unrelated reasons, leaving 22 participants (ten denosumab) for analysis 
of the primary outcome. There were 83% fewer osteoclasts at the osteolysis membrane-bone 
interface (median 0∙05/mm [IQR 0∙11] versus 0∙30/mm [0∙40], p=0∙011) in the denosumab 
versus the placebo group. No deaths or treatment-related serious adverse events occurred. In 
four of 11 participants randomised to denosumab seven adverse events occurred, including 
one serious adverse event. In five of 13 participants randomised to placebo ten adverse 
events occurred, including three serious adverse events.  
Interpretation To our knowledge, this is the first clinical trial of an investigational drug for 
osteolysis that demonstrates tissue-specific biological efficacy. These results justify the need 
for trials that target earlier-stage disease to test for clinical efficacy in reducing the need for 
revision surgery.  
Funding Amgen 
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RESEARCH IN CONTEXT 
Evidence before this study  
We searched MEDLINE and PubMed for “total hip arthroplasty” (THA) and “Denosumab”, 
filtering by “clinical trial” and “osteolysis” or “aseptic loosening”. We identified no 
completed trials reporting the use of denosumab to treat periprosthetic osteolysis or aseptic 
loosening. When the filters “osteolysis” and “aseptic loosening” were removed, we identified 
2 recent clinical trials showing the effect of denosumab in maintaining bone mineral density 
around the prosthesis over the first 2 years after primary surgery, an effect previously 
established using bisphosphonates. We found no reports on the effect of denosumab on later 
bone loss, osteolysis, aseptic loosening or revision risk.  
Added value of this study 
The only established treatment for prosthesis-related osteolysis after joint replacement is 
revision surgery, which carries substantially greater morbidity and mortality that primary 
joint replacement. This proof-of-concept study shows that a single 60mg dose of the 
monoclonal antibody to receptor activator of NFκB ligand, denosumab, is effective in 
reducing osteoclast number, eroded surface and bone turnover within established, 
symptomatic osteolytic lesions after THA.  
Implications of all the available evidence 
These data provide the biological evidence base necessary justify phase three trials in 
participants with earlier-stage disease to test for clinical efficacy in reducing rates of disease 
progression and the need for revision surgery. The establishment of such an alternative 
therapy would reduce the clinical and economic burden caused by joint replacement failure. 
4 
INTRODUCTION 
Despite ongoing advances in technology resulting in improved survival,1 prosthesis wear-
induced osteolysis leading to loosening remains the most frequent reason for revision surgery 
to a total hip replacement (THA) across Europe, Australasia, and Canada (Appendix, page 1). 
For example, in the period January 2014 to December 2018, osteolysis and aseptic loosening 
accounted for 20,646 of 38,550 (53%) of all revision procedures reported to the NJR in England 
and Wales.2 Osteolysis arises as an innate immune inflammatory response to the prosthesis 
materials and is characterised by the development of a granulomatous membrane at the 
prosthesis-bone interface.3 Pro-inflammatory cytokine release from the membrane leads to 
osteoclast activation, focal bone resorption and prosthesis loosening, resulting in pain and 
disability that requires revision surgery.4 Revision surgery is associated with a three-to-eight-
fold greater hospital mortality, higher morbidity and risk of re-revision, a smaller improvement 
in patient-reported and functional outcomes, and costs healthcare systems approximately twice 
as much as primary surgery.2,5 
There are currently no established alternative treatments to revision surgery for osteolysis. To 
date, the most extensively investigated group of drugs explored are the bisphosphonates. Whilst 
observational studies have associated bisphosphonate use with a lower incidence of prosthesis 
revision,6 these findings are not supported by clinical trial data. Rubash et al, in a randomised 
clinical trial of 123 participants (78 men, 45 women, mean age 63 years) with established 
femoral osteolytic lesions at 16 centres in the United States, found that daily oral administration 
of the bisphosphonate alendronate (10mg or 35mg versus placebo) did not affect change in 
radiological lesion size, visual analogue pain score, or likelihood of progression to revision 
surgery over 18 months.7 Animal models that mimic osteolysis have shown that suppression 
of osteoclast activity through modulation of receptor-activator of NFκB (RANK) signalling 
inhibits bone resorption and is more effective than bisphosphonates in reducing osteoclast 
numbers and osteolytic lesion size.8,9 
Denosumab is a fully human monoclonal antibody with a high affinity for RANK ligand 
(RANKL) that can bind and neutralize the activity of human RANKL. Denosumab at the 60mg 
dose has marketing approval in the United Kingdom for the treatment of post-menopausal 
osteoporosis. In rheumatoid arthritis, a condition also characterised by increased RANKL 
expression and focal bone erosion, denosumab is also effective in reducing bone erosions yet 
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bisphosphonates have been ineffective.10,11 Furthermore, a head-to-head comparison of 
denosumab versus the bisphosphonate alendronate found the bisphosphonate group to have 
progression in size of erosions whereas the denosumab group experienced reduced bone 
erosion size over 6 months following treatment.12  
In this study, we aimed to assess the effect and short-term safety of a single 60mg dose of 
denosumab on tissue-specific osteolytic lesion activity in patients with symptomatic, 
radiographically confirmed osteolysis after THA and who were awaiting revision surgery. 
Our primary hypothesis was that the group receiving denosumab treatment will have a lower 
osteoclast number within osteolytic lesions compared to the placebo group. The successful 
validation of this proof-of-concept would justify phase three trials in participants with earlier-
stage disease to test for clinical efficacy in reducing rate of osteolysis progression and the 
need for revision surgery. 
METHODS  
Study design and governance 
This single-centre, randomised, double-blinded, placebo-controlled, phase two superiority 
trial was conducted at Sheffield Teaching Hospitals NHS Foundation Trust. Ethical approval 
for the trial was provided by NRES Committee Yorkshire & The Humber – Leeds West 
(REC reference 11/YH/0252). We obtained written, informed consent from all participants. 
The trial was done and analysed according to the protocol that is openly available at 
http://dx.doi.org/10.17632/gp264xp3rd.1. The trial is registered with the EU Clinical Trials 
Register (EudraCT 2011-000541-20), and has clinical trial authorisation from the MHRA 
(21304/0239/001-0001). Sheffield Teaching Hospitals NHS Foundation Trust were the trial 
sponsor and monitor. They verified adherence to protocol, completeness and accuracy of the 
data, and that database verification and lock was complete prior to unblinding. The sponsor 
reviewed all adverse events (reporting to REC and MHRA, as required) and performed ad-
hoc visits to verify case record files. A Trial Steering Committee, comprising JMW, RE, and 
other investigators of the host department reviewed trial conduct at monthly meetings and 
advised the sponsor in accordance with Good Medical Practice.  
Participants 
Patients were identified in arthroplasty clinics for possible participation by SCB, AG, AJH, 
RMK, MWT, and JMW and formally screened for eligibility by the study research nurse 
6 
(AGr). Those greater than 30 years of age undergoing revision THA for radiologically-
confirmed periprosthetic osteolysis affecting either the femur or pelvis (with or without 
concurrent prosthesis loosening) and listed for revision surgery were eligible to take part in 
the trial. Patients with a metal or ceramic on conventional polyethylene bearing were 
included, as were cemented, hybrid and cementless methods of prosthesis fixation. Patients 
who had used oral bisphosphonates within the last twelve months or have had greater than 
three years of cumulative use were not eligible for the study. Any use of intravenous 
bisphosphonates, fluoride, strontium, parathyroid hormone or its derivatives, anabolic 
steroids or testosterone, corticosteroids, systemic hormone replacement therapy, selective 
oestrogen receptor modulator, tibolone, calcitonin or calcitriol were excluded. Patients 
suffering from hypocalcaemia or having a history of either Paget’s disease of the bone, 
rheumatoid arthritis or malignancy were also not eligible. Patients in whom denosumab is 
contraindicated along with those who were pregnant, breast feeding or had a known 
prosthesis infection were also excluded. Recruitment was stopped when 22 participants had 
completed the trial procedures since this was expected to provide >80% power to meet the 
primary endpoint. 
Randomisation and masking 
Following enrolment, participants received a study number and were randomly allocated 
(1:1) to a single subcutaneous injection either denosumab 60mg or placebo by an independent 
pharmacist using Documenta Geigy Scientific random number tables, sixth edition. The 
pharmacist stratified the randomisation in blocks of 10 to produce an equal number of 
treatment/placebo allocations for up to 30 participants. The dose of 60mg denosumab was 
selected as a dose-ranging study in rheumatoid arthritis, as a model of inflammatory 
osteolysis, had previously shown efficacy in trials at this dose on MRI erosion score and 
modified Sharp erosion score.13 The treatment allocation was known only to the independent 
pharmacist. Denosumab (60mg in 1mL solution) and matching placebo were prepared by 
Amgen Inc, according to the allocation schedule and supplied to the independent pharmacist 
by unique pack number that mapped to the study number. Both preparations appeared 
identical apart from the pack number identifier. Participants, investigators, outcome 
assessors, and care providers were masked to the treatment groups until analysis of the locked 
trial database following the final study procedures.  
Procedures 
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At the screening baseline visit (-2 weeks) demographic data and a medical history was 
collected, and blood samples for full blood count, erythrocyte sedimentation rate, C-reactive 
protein, urea and electrolytes, estimated glomerular filtration rate and serum calcium were 
taken. Clinical assessments (vital signs, changes to medical history and drugs), patient and 
clinician-reported outcomes (measured by Oxford14 and Harris15 hip scores, respectively), 
and adverse events were recorded at every visit. (weeks -2, 0, 4, 8, and 14). Blood and urine 
samples were taken for assessment of biochemical markers of bone turnover at weeks -2, 0, 
4, and 8. The bone resorption markers C-telopeptide of type-I collagen (CTX) and tartrate-
resistant acid phosphatase 5b (TRAP5b) were measured from serum by Elecsys β-Crosslaps 
assay (Roche Diagnostics, Indianapolis, IN) and ELISA (Nittobo Medical Ltd, Fukushima, 
Japan), respectively. The bone resorption markers α-CTX and β-CTX were measured by 
ELISA (Immunodiagnostic Systems, Ltd, Boldon, UK) from fasting morning urine samples. 
The bone formation marker total N-terminal propeptide of type-I procollagen (PINP) was 
measured from serum by Elecsys assay. All assays were performed as a single batch at the 
end of study following storage at -80°C. The study intervention was administered at visit 2 
(week 0). A cone-beam computed tomography scan of the hip was made at the same visit to 
evaluate the extent of the osteolysis, defined using the American Academy of Orthopaedic 
Surgery (AAOS) classification system,16,17 and to determine whether osteolysis involved the 
pelvis and /or the femur. Participants underwent revision surgery at week 8 (±2 weeks). At 
surgery, bone involvement and AAOS bone loss grade was confirmed by direct inspection. 
Representative biopsies of the osteolytic membrane and its underlying bone at the sites of the 
major osteolytic lesions were taken using a dedicated 6mm internal diameter bone biopsy 
trephine. The biopsy samples were fixed in 10% neutral buffered formalin prior to 
decalcification for a minimum of 3 months in EDTA. After decalcification was completed, 
samples were dehydrated, wax-embedded, sectioned at 4μm and stained for osteoclasts by 
tartrate-resistant acid phosphatase stain according to standard protocols. 
All non-surgical and non-radiological study visit procedures including treatment allocation, 
were performed by AGr. Radiological procedures were supervised and reported by NH, 
confirmation of the clinical and radiographic diagnosis was made by JMW, surgical 
procedures were made by SCB, AG, AJH, RMK, MWT, and JMW. Tissue biopsy sample 
processing was made by an experienced histology technician (OG) overseen by DH, and 
biochemical markers of bone turnover were assayed by the same bone biochemistry 
technician (FG). Histomorphometric measurements were made at x20 magnification on a 
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Leica DRMB fluorescence microscope (Leica Microsystems, Milton Keynes, UK) using 
Osteomeasure software (Osteometrics Inc, Atlanta, GA), according to established definitions 
and methods.18 All measurements were made in duplicate by MMM. Osteoclasts were 
defined as TRAP positive cells that stain red with at least one distinct nucleus visible. Only 
osteoclasts located within one cell distance from the osteolytic membrane-bone interface 
were counted. Osteoblasts were defined by the presence of a minimum of 3 adjacent cells 
with at least one osteoblast with a clear eccentric nucleus, cuboidal in shape and plump. 
Eroded surface was defined as a part of the osteolytic membrane-bone interface in which the 
bone had been eroded but was osteoclast negative. Quiescent surface was considered the 
‘inactive’ surface and was calculated by subtracting osteoclast surface, osteoblast surface and 
eroded surface from total osteolytic membrane-bone surface. Areas that did not include 
osteolytic membrane-bone interface were not measured. The immunohistochemistry slides 
were prepared by a histology technician (MG) using standard methods and read by OG. For 
Ki-67, optimised Ki-67 primary antibody diluted 1:400 (Dako, M7240) was applied and 
incubated overnight at 4C, followed by the secondary antibody in diamino-benzidine 
chromogen reagent applied for 4 minutes and counterstained with Gill’s Hematoxylin. For 
Caspase 3, polyclonal rabbit Caspase 3 diluted 1:400 (Cell Signalling, Ref-Ab9661) was 
applied using the same protocol. All slides were dehydrated and mounted with DPX 
mountant (Sigma, Ref-06522). Human tonsil tissue served as a positive and negative control. 
The negative control was prepared by omitting the primary antibody.  
Outcomes 
The primary outcome was the number of osteoclasts per millimetre of osteolytic membrane at 
the osteolytic membrane-bone interface at week 8 as assessed by static histomorphometry. 
The secondary outcomes were: The number of osteoblasts per millimetre of membrane, the 
length of osteoclast surface, eroded surface, and quiescent surface, expressed as a percentage 
of the total length of osteolytic membrane-bone interface as assessed by static 
histomorphometry; Percentage cell proliferation and apoptosis throughout the osteolysis 
membrane as assessed by Ki-67 and Caspase-3 immunostaining, respectively; systemic bone 
resorption and osteoclast number at weeks -2, 0, 4, and 8 as assessed by serum CTX and 
TRAP-5b, respectively; Relative resorption rates of newly formed versus mature collagen at 
weeks -2, 0, 4, and 8 as assessed by the ratio of urinary α-CTX to β-CTX (and corrected for 
urine concentration by urinary creatinine); And systemic bone formation rate at weeks -2, 0, 
4, and 8 as assessed by serum PINP. The safety outcomes were the adverse events recorded at 
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weeks 0, 4, 8 and 14; and patient and clinician-reported outcomes at weeks 0, 4, 8, and 14, as 
assessed by Oxford and Harris Hip Score, to identify more subtle potential clinical harms 
associated with the treatment; and evidence of bone fracture or other prosthesis-related 
complication at week 14 as assessed by plain radiograph of the hip. 
Statistical analysis  
The sample size was based on detecting a 50% difference in the absolute number of 
osteoclasts per millimetre of osteolytic membrane at the osteolytic membrane-bone interface 
(the primary outcome) between the denosumab group and placebo group (see protocol page 
29, http://dx.doi.org/10.17632/gp264xp3rd.1). We chose this effect size to be consistent with 
the effect of denosumab on osteoclast number in iliac crest biopsies from the STAND and 
FREEDOM osteoporosis studies,19 noting that the biological mechanism for the osteoclast 
activity differs between the diseases and that there are no established histomorphometric 
standards or minimally important differences for wear-particle-induced osteolysis. The data 
used to inform the power calculation were taken from counts of osteoclast number in routine 
histological bone-interface membrane biopsies from archived histology samples in 10 
patients with prosthesis-related osteolysis after cemented, hybrid, and cementless THA, and 
ranging in grade from linear through to expansile osteolysis. Power was estimated by 
simulation using an estimated mean (standard deviation) osteoclast number of 1∙8 (0∙6) and 
0∙9 (0∙6) in the control and treatment groups, respectively. At this effect size, a sample of 10, 
12 and 15 per group gave a power of 86%, 92% and 97% respectively, assuming a normal 
distribution and a two-sided alpha of 0∙05. In the trial, the study data were not normally 
distributed for the primary outcome and the primary analysis was performed by Mann-
Whitney U test on the median rank between-group difference in osteoclast number in 
participants who underwent revision surgery at week 8.  
All between-group secondary outcomes were analysed by Mann-Whitney U test in 
participants who underwent revision surgery at week 8. For the bone turnover markers, 
between-group comparisons were made on the marker change between baseline and week 8, 
with the baseline value calculated as the mean of the week -2 and week 0 measurement. 
Within-group biomarker changes between baseline and week 8 were analysed by Wilcoxon 
test. Bone turnover marker concentrations below the assay detection limit were assigned the 
lowest quantifiable value within the detectable range of the assay.  
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Adverse events were analysed between-group by Fisher exact test in all participants who 
received study drug. The patient and clinician-reported outcomes were analysed by between-
group median score change between baseline and the end of the trial (week 14) by Mann-
Whitney test in all participants who underwent revision surgery. Between-group differences 
in hip x-rays at week 14 were analysed qualitatively. All statistical analyses were made two-
tailed using SPSS version 25 (IBM, New York, NY). We considered p values of less than 
0∙05 statistically significant. 
Role of the funding source 
This study was funded by Amgen, Inc as an investigator-led study. The funder commented on 
the study design, but had no formal role in its development, nor in the data collection, 
analysis, interpretation, or writing the report. MMM, RJL and JMW had full access to all the 
study data and JMW had final responsibility for the decision to submit for publication.    
RESULTS 
Between December 12, 2012 and June 24, 2018, 51 patients were reviewed for eligibility, of 
whom 24 were enrolled (Figure 1). Two participants were withdrawn between treatment 
allocation and surgery for medical fitness reasons unrelated to the study treatment (1 from 
each treatment group, see adverse events), leaving 10 participants who received 60mg 
subcutaneous denosumab and 12 who received placebo in the per-protocol analysis. Baseline 
characteristics of the participants are shown in Table 2. Both baseline demographics and 
osteolytic lesion distributions were similar between the treatment groups.  
For the primary outcome there were 83% fewer osteoclasts at the osteolysis membrane-bone 
interface (median 0∙05/mm [IQR 0∙11] versus 0∙30/mm [0∙40], p=0∙011) in the denosumab 
group versus the placebo group (Figure 2). For the secondary histological outcomes, the 
osteoclast surface was 87% lower in the denosumab group (0∙14% [0∙33] versus 1∙04% 
[1∙22], p=0∙0089), and the eroded surface was 72% lower (0∙22% [0∙48] versus 0∙78% [1∙02], 
p=0∙015). The osteoblast number was 90% lower (0∙04/mm [0∙13] versus 0∙41/mm [0∙54], 
p=0∙017) and the osteoblast surface was 91% lower (0∙05% [0∙15] versus 0∙53% [0∙91], 
p=0∙015) in the denosumab versus placebo group. The most common surface in both 
treatment groups was the quiescent surface. This surface was 2% greater in the denosumab 
versus placebo group (99∙4% [0∙4] versus 97∙8% [2∙2], p=0∙0041). Immunocytochemistry for 
cell proliferation (Ki67) and apoptosis (Caspase 3) showed no differences between the groups 
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(appendix p 2, p>0∙05). The amount of osteolysis membrane-bone surface interface identified 
and quantitated was similar in both treatment groups (appendix p 3, p>0∙05). The coefficients 
of variation of the duplicate histomorphometry measurements are shown in appendix p 4. 
In the denosumab group there was an acute fall in both the serum and urinary markers of 
bone resorption after drug administration, reaching a nadir at week 4 that was maintained 
until revision surgery at week 8 (Figure 3A to 3E). No change in these markers was observed 
in in the placebo group (between group absolute difference p<0∙0003 all biomarkers). No 
change in the ratio of urinary α:β CTX was observed over the study period, nor any 
differential change between treatment groups (p=0∙31) to suggest a change in the ratio of 
immature to mature bone resorption induced by the treatment.  Following treatment 
administration a fall in the bone formation PINP was also observed in the denosumab group, 
reaching 56% at week 8, whilst no significant change was observed in the placebo group 
(Figure 3F, between group absolute p<0∙0001).  
Seventeen adverse events were recorded across all enrolled participant over the study period, 
seven in the denosumab group and ten in the placebo group (p=0∙54) and are listed in Table 
3. No life-threatening, disabling, or death adverse events were recorded. Two events of
arthralgia were reported, and considered possibly related to the drug. One occurred in a
denosumab recipient and the other in a placebo recipient. Two participants were withdrawn
from the study after treatment allocation and prior to revision surgery. One was withdrawn
from the denosumab group for a new diagnosis of oesophageal cancer. The other was
withdrawn from the placebo group because they required further anaesthetic assessment prior
to surgery that placed them out of study window for the primary outcome. This was not
recorded as an adverse event. One participant in the placebo group experienced recurrent
dislocations of the hip following revision surgery, requiring a further revision of the
acetabular component before the week-14 safety follow up visit.
No significant changes in clinical outcome scores were identified over the study period, 
except for a modest improvement over the 6 weeks following revision surgery in the placebo 
group (Appendix p5, p<0.05). No differences in these outcomes between the treatment 
groups were identified at any time point (p>0∙05). The safety follow up radiographs showed 
no qualitative evidence of prosthesis or bone-related complications in either treatment group, 
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with the exception of the placebo group participant with recurrent dislocation who underwent 
second revision prior to the week 14 imaging. 
DISCUSSION  
To date, there are no pharmacological or biological solutions to the problem of inflammatory 
osteolysis after joint replacement. Our proof of concept study assessed the effect of the 
RANKL monoclonal antibody denosumab in reducing osteolytic lesion activity in 
participants with symptomatic osteolysis after THA. A single 60mg dose of denosumab 
resulted in a substantial reduction in osteoclast number and other histomorphometric 
measures of lesion activity within 8 weeks of administration. Denosumab treatment also 
reduced systemic biochemical markers of bone turnover and was well-tolerated when 
compared with placebo. The number of adverse events in both study arms was similar, and 
was consistent with the relatively high morbidity associated with revision joint replacement 
surgery. The clinical outcomes data was consistent with the denosumab intervention not 
causing any additional harm.  
Several lines of investigation have indicated a central role for RANK signalling in osteolysis. 
Retrieval studies of interface membranes and hip synovial fluid taken at revision surgery 
show elevated levels of M-CSF, RANKL and an increased RANKL/ osteoprotegerin (OPG) 
ratio.20-22 RANKL mRNA expression in osteolytic lesion interface tissues correlates with 
lesion size and polyethylene wear volume;23 and circulating levels of RANKL protein and an 
increased RANKL/OPG protein ratio are associated with clinical osteolysis.24 Fibroblasts 
retrieved from interface membrane and exposed to particle debris express RANKL,25 and 
when co-cultured with human monocytes they induce osteoclast formation and lacunar bone 
resorption.26 Further, RANK -/- knock-out mice do not develop calvarial osteolysis or 
increased osteoclast number in response to a particulate stimulus, despite a local 
inflammatory cellular tissue infiltrate response.27  
Whilst histomorphometry data from the FREEDOM and STAND studies demonstrated a 
similar magnitude of suppression of osteoclast number in iliac crest biopsies of patients with 
post-menopausal osteoporosis,19 to our knowledge this study represents the first clinical 
investigation of the effect of this intervention on biological activity within inflammatory 
osteolytic lesions for which both the initiating stimulus and biological mechanism are 
different. The histomorphometric and biomarker data indicate suppression of bone turnover 
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activity at both local and systemic levels by the administered denosumab at the time of 
biopsy collection. This time point was chosen to coincide with the anticipated maximal 
efficacy of the drug, as suggested by systemic biomarker data from the FREEDOM trial.28 
The Ki67 and Caspase 3 data further suggest that whilst the denosumab reduced the bone cell 
count at the membrane surface there was no indication that the drug had an effect on general 
cellular proliferation or apoptosis within the cell membrane, as these markers are not specific 
to bone cells. 
This direct biological efficacy data provides evidence of effect size to inform power 
calculations on the numbers of participants required for a phase three study using symptom 
and lesion progression, and the need for revision surgery as the outcomes. From this data, we 
estimate that 80 participants randomised at 1:1 ratio would need to be recruited to a study 
examining the effect of denosumab on change in radiographic lesion size with an alpha of 
0.05 and power of 90%. This assumes a conservative 50% suppression in eroded surface that 
directly corresponds with change in lesion volume, that osteoclast activity accounts for all 
bone resorption and that the measurement technique used to assess the outcome is sufficiently 
sensitive.  
This study has limitations. The primary criteria for inclusion in the study was wear-particle 
associated osteolysis in the presence of a polyethylene-containing bearing. Osteolysis occurs 
around prostheses that are fixed to the adjacent bone with cement and those that are fixed 
without cement, and thus both fixation methods were represented amongst the participants. 
We used a single-dose intervention to demonstrate the biological proof of concept by 
studying patients whose disease was sufficiently severe to require revision surgery and used 
that opportunity to study the effect of the drug on osteolytic lesions directly. This approach 
had challenges. The study was slower to recruit than anticipated, as the sample population 
was a subset of all osteolysis patients, and there was little perceived personal benefit to 
participation as the primary outcome did not obviate the need for revision surgery. However, 
the value of direct observation of denosumab on lesion activity provides clear evidence to 
justify the conduct of further trials examining clinical outcomes. Such studies could be 
conducted in patients in whom the lesions were less advanced and in whom loosening of the 
prosthesis was not already established at study enrolment. In order to demonstrate an effect 
that alters the natural clinical history of the disease, repeated dosing would likely be required, 
and the clinical outcomes may not directly follow the biological effects nor be sustained. 
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What are the potential risks of using denosumab in patients with osteolysis? Denosumab has 
been widely used over the past 10 years for the treatment of postmenopausal osteoporosis. 
However, there was evidence from the 10-year Phase 3 FREEDOM Trial that there is an 
increase in the risk of osteonecrosis of the jaw and atypical femur fractures.29. The risk of 
these outcomes relates to duration of treatment. In the FREEDOM trial, none of the 13 cases 
of osteonecrosis of the jaw and none of the two cases of atypical femur fracture occurred 
within the first three years of therapy. There is also evidence for a period of accelerated bone 
loss in the first year of stopping denosumab therapy that is likely the result of high bone 
turnover and the consequence is an increase in the risk of multiple vertebral fractures.30 Their 
relevance to the dosing, duration and route of administration that may be required in the 
management of periprosthetic osteolysis is yet to be determined. 
In conclusion, the results of this proof-of-concept clinical trial indicate that denosumab is 
effective at reducing bone resorption activity within osteolytic lesion tissue and is well-
tolerated within the limitations of the single dose used here. Given this demonstration of 
biological effect, phase three studies are warranted to examine the clinical efficacy of 
denosumab in halting the progression of osteolytic lesions using clinical outcome as the 
measure of efficacy. 
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LEGEND TO FIGURES 
Figure 1: Trial profile 
Figure 2: Histomorphometric outcomes. Truncated violin plots showing individual 
datapoints, coloured dashed error bar is median and black dotted error bars show interquartile 
range. Analysis is between-group by Mann-Whitney U test of ranks. 
Figure 3: Bone turnover marker outcomes. Absolute median and interquartile range values 
for each marker are show in top panel, together with analysis of within-group changes versus 
baseline by Wilcoxon test. Bottom panel shows the estimated difference (ED) of denosumab 
minus placebo medians and 95% confidence interval at each time point, using the Hodges 
Lehmann estimator. Between-group comparisons were made on the absolute marker change 
by Mann-Whitney U test of ranks, with the baseline value calculated as the mean of the week 
-2 and week 0 measurement.. Only significant p-values are shown. Arrow shows drug 
administration point.
1 
Table 1. Indication for revision hip replacement surgery across large publically reported European, Australasian and Canadian joint replacement 
registries.  
†Single-stage revisions only, indications are not mutually exclusive; ††figures for aseptic loosening and osteolysis (without loosening) combined;*absolute 








Most frequent revision 
indication††
2nd most frequent 
revision indication
3rd most frequent 
revision indication Web link to report
England & 
Wales† 2019
























































































































































Week 14  
Assessed for eligibility between 
December 19, 2012 and June 24, 2018 
(n= 51) 
Randomized (n= 24) 
Excluded  (n= 27) 
 Not meeting inclusion 
criteria (n= 6) 
3 Bisphosphonates   
1 History of Cancer 
 1 Oral steroids 
 1 Ongoing intra-articular 
steroids to other joints 
 Declined to participate  
(n= 20) 
 Other reasons (n= 1) 
1 Denosumab 
contraindicated – 
pending dental surgery 
 
Allocated to denosumab  
(n= 11) 
  Received allocated 
denosumab (n= 11) 
 Did not receive allocated 
intervention (n= 0) 
 
Allocated to placebo  
(n= 13) 
 Received allocated 
placebo (n= 13) 
 Did not receive allocated 
intervention (n= 0) 
 
Underwent revision THA 
where biopsies of membrane 
taken (n=10) 
Underwent revision THA 
where biopsies of membrane 
taken (n=12) 
Analysed in per-protocol 
population (n=10) 
Analysed in per-protocol 
population (n=12) 
 
Analysed in safety 
population (n=11) 
Analysed in safety 
population (n=13) 
Withdrawn from surgery 
(n= 1, oesophageal 
cancer) 
Withdrawn from surgery 
(n= 1, medically unfit 



























































































































































































































































































































Appendix Figure: Immunohistochemistry outcomes. Truncated violin plots showing individual 
datapoints, coloured dashed error bar is median and black dotted error bars show interquartile 










































B Caspase-3 positive cells
3 
Appendix Figure: Length of bone-pseudomembrane interface measured in each participant 
group. Truncated violin plots showing individual datapoints, coloured dashed error bar is median and 




























Appendix Table - Intra-observer variation in histomorphometric measurements. All outcomes 
were measured independently by the same observer with a gap of at least 2 weeks between 
measurements 
Histomorphometry Indices Coefficient of Variation (%) 
Osteolytic membrane-bone interface 3∙1 
Number of osteoclasts/membrane (mm) 7∙0 
Number of osteoblasts/membrane (mm) 10∙7 
Osteoclast surface (%) 15∙7 
Osteoblast surface (%) 21∙4 
Eroded surface (%) 55∙9 
Quiescent surface (%) 0∙4 
5 
Appendix Figure: Patient and clinician-reported safety outcomes. Absolute median and 
interquartile range values for each measure are show in top panel, together with analysis of within-
group changes versus baseline by Wilcoxon test. Bottom panel shows the estimated difference (ED) 
of denosumab minus placebo medians and 95% confidence interval at each time point, using the 
Hodges Lehmann estimator. Between-group comparisons were made on the absolute marker change 













































B Harris hip score
p=0.034
